(Q40197212)

18 September 2017

1 reference

title

Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses (English)

1 reference

18 September 2017

1 reference

Ahmed AR

1

1 reference

18 September 2017

Hombal SM

series ordinal

2

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 December 1984

1 reference

Journal of the American Academy of Dermatology

18 September 2017

published in

1 reference

18 September 2017

volume

11

1 reference

18 September 2017

issue

6

1 reference

18 September 2017

page(s)

1115-1126

1 reference

18 September 2017

cites work

The oxazaphosphorines

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Effects of cyclophosphamide on lymphoid tissues labelled with 5-iodo-2-deoxyuridine- 125 I and 51 Cr.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Specific Acquired Immune Unresponsiveness to Contact Allergens with Cyclophosphamide in the Mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

The effect of cytotoxic drugs on graft-versus-host disease in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

19S and 7S Antibody Production in the Cyclophosphamide- or Methotrexate-treated Rat

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Effect of Cyclophosphamide on Immunological Control Mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide inhibited B cell receptor regeneration as a basis for drug-induced tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Immunoregulation in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

The effect of cyclophosphamide on immunological memory

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Effect of large intermittent intravenous doses of cyclophosphamide in lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the english literature

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cytotoxic drug-induced pulmonary disease: update 1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Sterility and testicular atrophy related to cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Gonadal dysfunction in patients receiving chemotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Genetic effects of cyclophosphamide, ifosfamide and trofosfamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

CONGENITAL ANOMALIES PROBABLY INDUCED BY CYCLOPHOSPHAMIDE

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Fetal effects during cyclophosphamide and irradiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Normal pregnancy in multiple myeloma treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Sister chromatid exchange in lymphocytes from patients with malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Sister chromatid exchange studies for monitoring DNA damage and repair capacity after cytostatics in vitro and in lymphocytes of leukaemic patients under cytostatic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Sister-chromatid exchanges and chromosal breakage in patients treated with cytostatics

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

CYTOLOGICAL STUDY OF THE EFFECT OF CYCLOPHOSPHAMIDE ON THE EPITHELIUM OF THE URINARY BLADDER IN MAN

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide and the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cancer in patients treated with immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

The Incidence Of Bladder Cancer after Cyclophosphamide Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Late hemorrhagic cystitis following low-dose cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Bladder malignancy in patient receiving cyclophosphamide for benign disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Possible anaphylactic reaction to intravenous cyclophosphamide. Report of a case

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Generalized urticaria to cyclophosphamide: Type I hypersensitivity to an immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Letter: Cyclophosphamide-induced nail pigmentation

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of mycosis fungoides with cyclophosphamide and chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

The treatment of mycosis fungoides with a new agent, cyclophosphamide (Cytoxan)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of mycosis fungoides with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Pemphigus vulgaris successfully treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Pemphigus Vulgaris Treated With Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of pemphigus with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Corticotropin and cortisone treatment for systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

CYCLOPHOSPHAMIDE TREATMENT OF KIDNEY DISEASE IN (NZB X NZW) F1 MICE

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide in lupus nephritis: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide in Treatment of Systemic Lupus Erythematosus: 7 Years' Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

A Sequential Trial Comparing Cyclophosphamide and Azathioprine as Adjuncts in the Treatment of Systemic Lupus Erythematosus*

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

NIH conference. Systemic lupus erythematosus: evolving concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

The systemic lesions of malignant rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Controlled trial of cyclophosphamide in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide Therapy for Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Long-term cyclophosphamide therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Toxicity of immunosuppressive drugs in man

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide-induced remissions in advanced polyarteritis nodosa

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Pyoderma gangrenosum with response to cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Psoriasis with Arthritis: Chemotherapy with Cyclophosphamide, Nitrogen Mustard and 6-Mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Explorations of antimitotic agents in the treatment of a congenital disease, Ichthyosis Linearis Circumflexa

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of eczema with cyclophosphamide and azathioprine*

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Cyclophosphamide therapy of Behcet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Immunosuppressive therapy in polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

"Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of refractory thrombocytopenic purpura with cyclophosphamine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

A survey of the effectiveness of cyclophosphamide in patients with severe aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Treatment of active chronic hepatitis with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Plasma cell interstitial pneumonia and macroglobulinemia. A response to corticosteroid and cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

Plasmapheresis and immunosuppressive drug therapy in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2884%2980193-0

7 January 2021

10.1016/S0190-9622(84)80193-0

Identifiers

DOI

1 reference

18 September 2017

1 reference